Podcasts about HLA

Í þættinum í dag ræða Söguskoðunarbræður sögu páfadæmisins, þessa fornu stofnunar sem hefur gegnt lykilhlutverki í kristinni trú og evrópskri sögu öldum saman. Mögulega er páfadómurinn eitt elsta embætti sem enn er mannað í okkar heimshluta, og varla fór framhja neinum þegar nýr páfi var kjörinn nú fyrir skömmu. Í þessum þætti ræða Ólafur og Andri um þróun og sögu páfans, löggildingu hans sem arftaki Péturs postula, deilur hans við konunga og keisara á miðöldum, klofninginn við austurkirkjuna, siðaskiptin og fleira og fleira.Er hinn heilagi faðir í Róm arftaki Krists á jörðu, eða er hann afurð veraldlegra og pólitískra hreyfinga eftir fall Rómarveldis? Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

We're back in the French Riviera for a very special episode, as Girls On Film returns to the 78th edition of the Cannes Film Festival. This year, host Anna Smith welcomed guests to the second Girls On Film Cannes Do at The Members Club. This glamorous networking event on the beach brought together filmmakers, critics, and creatives celebrating the power of women in cinema. In this episode, you'll hear reflections from our community on what Girls On Film means to them. Later on in the episode Anna reunites with film journalist Wendy Ide who reflects on this year's films, which she says have been of a consistently high standard. Wendy shares her standout picks from the festival, from the fiercely divisive Die, My Love, a visceral exploration of the raw edges of motherhood and mental unravelling, to Sound of Falling, a haunting meditation on how trauma echoes through time and place. She also dives into Sirât, an allegorical road movie, in which gender and disability are refreshingly incidental, not defining. Plus other titles that are already generating serious awards buzz. And finally, we're joined by Liza van der Smissen and Nicole Lieberman, founders of the Female Film Club. This trailblazing global network uplifts women in the industry through practical workshops, seminars and a thriving, supportive community. They share the story behind their mission and how they're helping to reshape the future of film, one powerful connection at a time. They also unveil an exciting new opportunity: a £10,000 investment in a short film, designed to give back to their talented global community. To enter from 16th June onwards, filmmakers must join their networking space. If you're looking to join a space that champions and supports women in film, don't miss out – click this link to join the Female Film Club: [link: https://female-film-club.mn.co/users/onboarding/choose_plan?plan_id=1818474&bundle_token=aca8b4a8f139016aca1a9fdc680a97a8&utm_source=manual] We would also like to thank our incredible sponsors for all their support: Col Needham and Karen Needham at IMDb: [link: https://www.imdb.com/title/tt18211920/?ref_=nv_sr_srsg_3_tt_8_nm_0_in_0_q_girls%2520on%2520film] Clare Bateman-King at Lilac Grove Entertainment: [https://lilacgrove.com/] JoJo Dye at JJD Consultancy: [link: https://jjdconsultancy.com/] Jane Owen at Jane Owen PR: [https://janeowenpr.com/] The House of Oria: [https://www.thehouseoforia.com/] Sunny Pal at Astella: [https://www.instagram.com/astellajewellery/?hl=en] HLA Agency: [https://hlaagency.co.uk/] Films mentioned in this episode: Die, My Love, Lynne Ramsay Eleanor the Great, Scarlett Johansson The History of Sound, Oliver Hermanus Mastermind, Kelly Reichardt My Father's Shadow, Akinola Davies Pillion, Harry Lighton Romería, Carla Simón Sirât, Oliver Laxe Sorry Baby, Eva Victor Sound of Falling, Mascha Schilinski The Secret Agent, Kleber Mendonça Filho Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold, who also produced this episode Audio Editor: Benjamin Cook Intern: Hattie Morris Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

Lella Erludóttur í Hlaðvarpinu hjá Óla Jóns Um Lellu Lella Erludóttir lýsir sér sem "konu margra hatta" - hún er markþjálfi, mannauðssérfræðingur og hefur reynslu sem markaðskona. Hún starfar nú sem sjálfstætt starfandi markþjálfi og segir markaðsþekkingu koma sér alltaf að notum, hvort sem það er í starfi eða daglegu lífi. Hvað er markþjálfun? Lella útskýrir markþjálfun sem sannreynda viðtalsaðferð þar sem markþjálfinn hýsir rýmið og stýrir ferlinu, en markþeginn stýrir viðfangsefninu. Markþjálfinn spyr kraftmiklar og ögrandi spurningar til að efla vitundarsköpun hjá markþeganum. Grundvallartrú markþjálfunar er að hver og einn markþegi sé hæfur, skapandi, úrræðagóður og hafi öll svörin innra með sér. Sérhæfing Lellu Lella hefur þrengt markhóp sinn og sérhæft sig í: * Starfstengdri markþjálfun * Loddaralíð (imposter syndrome) - þar sem fólk líður eins og það sé að feika það og óttist að aðrir komist að "hinu sanna" Hún rekur sex klukkustunda námskeið um loddaralíð og tekur fólk í markþjálfun sem glímir við þetta vandamál. Starfstengd tímamót Lella vinnur mikið með fólk sem er að upplifa starfstengd tímamót: * Þá sem vilja meiri ábyrgð eða fleiri verkefni * Fólk sem vill skipta um starf eða veit ekki hvað það vill gera * Þá sem eru að jafna sig eftir veikindi eða kulnun * Fólk sem flytur aftur til landsins Faglegar vottanir Lella tilheyrir ICF (alþjóðasamtökum markþjálfa) með PCC vottun, sem þýðir: * ACC: Grunnmenntun + 100 klukkustundir í markþjálfun * PCC: 175 klukkustundir menntun + 500 klukkustundir markþjálfun * MCC: Enn meiri menntun + 2.500 klukkustundir markþjálfun NBI huggreiningar Lella er vottuð til að gera NBI huggreiningar sem mæla hugsnið í fjórum flokkum: * Gulur: Skapandi, lausnamiðað, opinn * Rauður: Félagslegur, mannlegur, tengsl * Grænn: Verndandi, skipulagður * Blár: Raunsær, staðreyndamiðaður Þetta tæki er hægt að nota á einstaklinga og teymi til að skilja vinnustaðamenningu betur. Vinnustaðamenning Lella útskýrir vinnustaðamenningu sem það hvernig samskipti fara fram og ferlar virka í raun og veru - ekki bara það sem stendur á veggnum. Hún leggur áherslu á að vinna þurfi með menningu frá grunni og upp, og að bæði leiðtogar og starfsfólk þurfi að vinna sína vinnu. Jafnvægi vinnu og einkalífs Frekar en að tala um jafnvægi lítur Lella á það að vinna og einkalíf ættu að styðja hvort við annað - vera samofin þannig að hvort um sig veiti virði og næringu. Helstu viðskiptavinir Lella segist aðallega fá til sín konur á einhvers konar tímamótum sem eru í aðstæðum sem þeim líður ekki vel í og vilja breytingar en vita ekki hvað eða treysta sér ekki til að sækjast eftir tækifærum. Árangursdæmi Lella nefnir dæmi um konu sem kom til hennar með það í huga að þurfa að sitja í óþægilegu starfi næstu 30 árin. Eftir sex tíma í markþjálfun hafði konan skýra sýn á hvað hún vildi, sagði upp starfi sínu og fékk að lokum starf sem stjórnandi í fyrirtæki þar sem henni líður vel. Hvar finn ég Lellu? https://www.lella.is/ https://www.facebook.com/lella.markthjalfi https://www.linkedin.com/in/lellaerludottir/ https://www.instagram.com/lella.markthjalfi/ https://www.tiktok.com/@lella.markthjalfi Viðtalið sýnir hvernig markþjálfun getur hjálpað fólki að finna skýrleika, sjálfstraust og stefnu í starfi og lífi.

Host Anna Smith brings you an exclusive conversation with the women of Mission: Impossible – The Final Reckoning, recorded live at London's Ham Yard Hotel. This latest instalment in the high-octane Mission: Impossible franchise sees Ethan Hunt and the IMF team race against time to confront the Entity, a rogue artificial intelligence threatening global destruction. Joining Anna for this special panel are two talents at the heart of the action: Pom Klementieff, who takes on the role of Paris, and Angela Bassett, returning as Erika Sloane, the President of the United States. Together, they delve into the challenges of working on one of cinema's most physically demanding franchises, explore the critical role costume design plays in shaping their characters, and reflect on the powerful, real-world impact of casting a Black woman as the US president in a fictional universe. Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Alex Jones Sound recordist: Erin Millican House band: MX Tyrants This episode is in partnership with Netflix © HLA Agency

In 1924, a surgeon and a pathologist had a conversation about some patients with multiple bowel polyps. The pathologist, Dr Cuthbert Dukes, and the surgeon, Mr JP Lockhart-Mummery, noted that patients had a family history of bowel cancer and could have hundreds of colonic polyps. They, with the help of HRJ Bussey, set up the Polyposis Registry. The registry collected information about these patients and the families from 1918 to 1954. They found that patients developed polyps in childhood, the risk of affected children was 50%, and cancer took 15 years to develop from first diagnosis. This was clearly a familial disease. Today, we know this a Familial Adenomatous Polyposis or FAP. The genetic basis for this condition was identified in the 1980s and 1990s. Professor Sir Walter Bodmer led a team to map the location of the Adenomatous Polyposis Coli (APC) gene involved. This is the story of Familial Adenomatous Polyposis (FAP) Our special guests: Professor Sir Walter Bodmer is a professor of the Cancer and Genetics laboratory and Department of Oncology at Oxford University. Areas of research include: HLA, population genetics, Human Genome Project, and mapped the APC gene. He was knighted in 1986. Dr Tristan Rutland is an Anatomical Pathologists, recipient of the Konrad Muller RCPA Outstanding Teaching Award (2020), and recipient of the Resident Advocate Award from the College of American Pathologists. Dr Emelia Ip is a trained medical oncologist, staff specialist in cancer genetics, and co-chair of EviQ Adult Cancer Genetics Reference Committee. Help support us on our donation page.See omnystudio.com/listener for privacy information.

Í þættinum í dag ræða Ólafur og Andri um hið svonefnda "ástand" á Íslandi í seinni heimsstyrjöld: Ástarsambönd íslenskra kvenna og breskra og bandarískra hermanna, og afskipti íslenskra yfirvalda af því.Hernámið hafði gríðarlegar samfélagslegar breytingar í för með sér fyrir Ísland. Með komu hernámsliðsins 1940-1941 streymdu tugir þúsunda hermanna til landsins og þegar mest lét var fjöldi setuliðsmanna á Íslandi nær helmingur íbúafjöldans. Sambönd íslenskra kvenna og setuliðsmanna ollu siðferðilegri skjálftaöldu hjá elítunni, og ríkisvaldið brást við af hörku. Fylgst var með ungum konum, haldið var skrá yfir sambönd þeirra og gripið til harðra aðgerða samkvæmt sérstökum lögum sem sett voru. Mikið hefur verið fjallað um "ástandið" á síðastliðnum áratugum í íslenskri sagnfræði, ekki síst í tengslum við sögulegt réttlæti, og þá sérlega hin síðustu ár eftir að skjöl urðu aðgengileg sem varpa ljósi á mögulega einar umfangsmestu njósnir íslenskra yfirvalda um einkalíf borgaranna fyrr og síðar.Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

Við ræðum við stjórnanda hlaðvarpsins Ein pæling, Þórarinn Hjartarson. Hlaðvörp skipta æ meira máli í þjóðfélagsumræðunni og við ætlum að ræða við stjórnendur hlaðvarpa í Lestinni næstu vikurnar.

Í dag byrjum við þáttinn á umfjöllun um vímuefnaröskun, sem er einn alvarlegasti heilbrigðisvandinn sem við glímum við – samkvæmt Alþjóðaheilbrigðisstofnuninni. Röskunin er þó meðhöndlanleg og við eigum meðferðir sem virka – en röskunin einkennist ekki síst af bakföllum og hindranirnar sem blasa við þeim sem sækja sér meðferð eru margar. Erla Björg Sigurðardóttir, lektor í félagsráðgjöf og framkvæmdastýra á áfangaheimili fyrir konur, Helena Gísladóttir, dagskrárstjóri meðferðar Krýsuvíkursamtakanna og MA-nemi í félagsráðgjöf og Sara Karlsdóttir löggiltur áfengis og vímuefnaráðgjafi og dagskrárstjóri meðferðar hjá Hlaðgerðarkoti setjast hjá okkur og ræða um félagslega stöðu einstaklinga í langtíma meðferð vegna vímuefnaröskunar. Hvað á að gera við rafhlöðuna úr rafmagnsbílnum þegar hann er hættur að ganga? Rúnar Unnþórsson, prófessor í iðnaðar- og vélaverkfræði við Háskóla Íslands, leitar nú svara við því en búast má við að innan fárra ára hafi fallið til mikið af slíkum rafhlöðum sem vel gætu átt gott og farsælt framhaldslíf. Og í lok þáttar ætlar Helga Lára Þorsteinsdóttir, safnstjóri RÚV, að kíkja við og deila með okkur gullmola úr safni Ríkisútvarpsins. Tónlist úr þættinum: Bridgers, Phoebe - Motion sickness. Fleet Foxes - Battery Kinzie. Stuðmenn - Vorið.

In this star-studded episode, Anna Smith and co-founder Hedda Lornie Archbold delve into two exciting new films led by complex and captivating women. First, Anna chats with Julia Louis-Dreyfus and Geraldine Viswanathan, stars of Thunderbolts*—the latest Marvel Cinematic Universe film. Together, they discuss their first meeting, stepping into a superhero world alongside Florence Pugh and bringing depth and humour to their roles. Then, Hedda speaks with producer Rosie Fellner and actor Elizabeth Reaser about The Uninvited—a darkly funny and deeply poignant film that explores gender, aging, and identity in Hollywood. Reaser portrays Rose, a once-famous actress whose life is upended by a mysterious guest at a glamorous Hollywood gathering. The film also stars Walton Goggins, Lois Smith, Eva De Dominici, Pedro Pascal, and Rufus Sewell, and is writer-director Nadia Conners' debut feature. Thunderbolts* landed in UK cinemas 1 May 2025 The Uninvited is in UK cinemas 9 May 2025 http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Hattie Morris Audio editor: Benjamin Cook House band: MX Tyrants Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

Our Lawyer, Jim Pocrass, assesses the lawsuit brought by Streetsblog Los Angeles editor Joe Linton. LA Metro has argued that because it's not the city, it doesn't have to make bike infrastructure when repaving city streets, as called for in ballot measure HLA. The agency claims it would have to destroy homes and buildings to both preserve parking and make space for bikes (3:40). The standoff between New York and the Federal government over congestion pricing, as told by Streetsblog NYC Editor Gersh Kuntzman (10:22). Bike JC's Vice President Tony Borelli, Trustees Emmanuelle Morgan and Deidre Newman, and bike maker Anke Irmscher on Jersey City's bike ecosystem and their place in it. (23:50).

In this episode Ethan, Nic, and Sully discuss the closure of Pike Place Market to cars, LA Metro's light rail expansion to LAX, and the idea of Freedom Cities. They explore housing challenges in cities like Baltimore and Philadelphia, the HLA lawsuit in Los Angeles, and the difficulty of making public transit profitable. The conversation highlights the importance of headways, accountability in urban planning, and balancing the roles of cars, transit, and AI in city governance.Send us a question: radiofreeurbanism@gmail.comPatreon: patreon.com/RadioFreeUrbanism Instagram: https://rb.gy/ezn9rzSully: https://www.youtube.com/@SullyvilleEthan: https://www.youtube.com/@climateandtransitNic: https://www.youtube.com/@nicthedoorLinksBest Side Cycling - Car Free Pike Place: https://www.youtube.com/watch?v=aVCvnZnqyEIFreedom Cities: https://tinyurl.com/2z8carjbHLA Lawsuit: https://www.streetsforall.org/blog/first-hla-lawsuit

VidRay deals with his son hitting milestones, and Ray becomes competitive. Brad never watched Free Willy. Chuck wonders what would overshadow Will Smith's Oscars Slap and bring him back to Hollywood dominance?Also: Edge of Tomorrow, the Cruel Intentions kiss, WWE's HLA, American Pie and ultimately - the death of the teen sex comedy.Video edit by Craig Depina@funbearablepod / funbearablepod.com-------------------------------This episode is brought to you by NARRAGANSETT BEER! Check out Narragansett Beer nationally and make sure to check out the new Narragansett brewery in Providence, RI if you're in the New England area!narragansettbeer.com / @gansettbeer-------------------------------#podcast #laugh #funny #movies

News: Healthy Streets LA, the ballot measure which requires Los Angeles to implement bike infrastructure every time city streets are repaved, is being ignored by the county's transportation agency, LA Metro. Taylor talks with the founder of Streets For All, Michael Schneider, who led the HLA campaign, and the Editor of Streetsblog LA, Joe Linton, who's now suing the city (1:33). It's been 100 years since the Los Angeles city council passed the ordinance which said that if you're walking you have to give right of way to drivers everywhere, except for particular crossings. New Mexico adopted the Stop as Yield Law for cyclists. Paris reduced speed limits on the Boulevard Périphérique from 70 to 50 km/hr, resulting in reduced traffic congestion, smoother traffic flow, fewer crashes, lower air pollution, and lower noise levels. https://www.apur.org/en/our-works/tracking-changes-boulevard-peripherique-and-green-belt-districts-october-2024-february-2025 London's Tweed Run ride is April 29. For National Autism Acceptance Month, Detroit's Neila Johnson has created the Cycling the Spectrum ride. Neila talks with Motown Trailblazers Bike Club President Reo Ramsey (24:35). Cross country solo cyclist Chris Casey tells the story of his ride across the U.S. (34:05). Bike Thought: The 85th Percent Rule, by Charles Marohn (54:36). Thanks Ted Rogers of BikinginLA.com.

Í þættinum í dag ræða Söguskoðunarmenn um samúræjana – stríðsmenn gamla Japans og táknmyndir japanskrar menningar. Samúræjarnir voru kjarninn í japönsku lénsskipulagi og áttu gullöld sína á  Tokugawa tímabilinu (1600–1868), þegar Japan var sameinað undir sterku miðstjórnarvaldi sjógúnanna. Þetta tímabil einkenndist af friði, einangrunarstefnu og blómaskeiði í menningu, listum og heimspeki. Samúræjarnir voru hermenn, aðalsmenn og embættismenn og gegndu lykilhlutverki í samfélagi þar sem heiður, hollusta og agi réðu ríkjum. Riddaralegur lífstíll og siðir samúræjanna byggði á bushidō, „leið stríðsmannsins“, og hafa þessir japönsku riddarar verið táknmynd hins forna Japans sem leið undir lok á 19. öld.Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

Andrés Magnússon og Stefán Einar Stefánsson ræða um hrakfarir ríkisstjórnarinnar frá þvi að hún tók við völdum fyrir þremur mánuðum, almennt um stöðuna í stjórnmálum, hvort að Stefán Einar sé að stefna að því að verða bæjarstjóri í Garðabæ, hvort að það sé nýtt vandamál fyrir ríkisstjórnina í vændum, hvernig stjórnarandstaðan mun standa sig, um óviðeigandi spjallgrúbbur og margt annað sem vert er að fjalla um á afmælis-bjórkvöldi Þjóðmála. Hlaðvarp Þjóðmála fagnar nú fjögurra ára afmæli og það er af nægu að taka.

Í þættinum í dag ræða Söguskoðunarmenn um stórveldisdrauma ítalska einræðisherrans Benito Mussolini og misheppnaðar tilraunir Ítalíu til að verða stórveldi á árunum 1923-1943.Eftir fyrri heimsstyrjöld fannst Ítölum þeir hafa verið sviknir um verðskuldað herfang  – Vittoria Mutilata eða „limlestur sigur“ var Versalafriðurinn kallaður. Þetta átti eftir að móta utanríkisstefnu Mussolinis, sem sóttist eftir því að gera Ítalíu að heimsveldi á ný, eða endurreisa Rómarveldi, eins og sagt er. Hann stefndi á eigin landvinninga í Afríku og á Balkanskaga og gekk til liðs við Hitler og Öxulveldin í aðdraganda ófriðarins mikla.Í seinni heimsstyrjöld stóð ítalski herinn frammi fyrir miklum erfiðleikum. Skortur á skipulagi, úrelt vopnabúnaður og óraunhæfar hernaðaráætlanir ollu því að ítölsk hernaðarframmistaða var hörmuleg. Frá innrásinni í Grikkland til ósigranna í Norður-Afríku og fall Ítalíu árið 1943, var herinn stöðugt háður stuðningi Þjóðverja.Í þessum fyrri hluta ræða Ólafur og Andri Ítalíu á millistríðsárunum í aðdraganda seinni heimsstyrjaldar.Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

Í þættinum í dag ræða Söguskoðunarmenn um stórveldisdrauma ítalska einræðisherrans Benito Mussolini og misheppnaðar tilraunir Ítalíu til að verða stórveldi á árunum 1923-1943.Eftir fyrri heimsstyrjöld fannst Ítölum þeir hafa verið sviknir um verðskuldað herfang  – Vittoria Mutilata eða „limlestur sigur“ var Versalafriðurinn kallaður. Þetta átti eftir að móta utanríkisstefnu Mussolinis, sem sóttist eftir því að gera Ítalíu að heimsveldi á ný, eða endurreisa Rómarveldi, eins og sagt er. Hann stefndi á eigin landvinninga í Afríku og á Balkanskaga og gekk til liðs við Hitler og Öxulveldin í aðdraganda ófriðarins mikla.Í seinni heimsstyrjöld stóð ítalski herinn frammi fyrir miklum erfiðleikum. Skortur á skipulagi, úrelt vopnabúnaður og óraunhæfar hernaðaráætlanir ollu því að ítölsk hernaðarframmistaða var hörmuleg. Frá innrásinni í Grikkland til ósigranna í Norður-Afríku og fall Ítalíu árið 1943, var herinn stöðugt háður stuðningi Þjóðverja.Í þessum seinni hluta ræða Ólafur og Andri Ítalíu í seinni heimsstyrjöld, gang stríðsins, bandalagið við Þjóðverja og fall Mussolinis 1943/1945.Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

In this special episode recorded at the Glasgow Film Festival, Jessica Lange joins Girls On Film host Anna Smith to reflect on her extraordinary career across stage and screen. She discusses her latest film, Long Day's Journey Into Night, which premiered at the festival, and shares insights into her rural Minnesota upbringing, early years studying mime in Paris, and her upcoming role as Marlene Dietrich. Jessica also revisits some of her most iconic roles, from portraying Frances Farmer in the heartbreaking biopic Frances to starring alongside Dustin Hoffman in the genre-defying comedy Tootsie. She also explores her more recent work on American Horror Story, which not only cemented her status as an acting legend but also introduced her to a new generation of fans. Beloved by Gen X and Gen Z alike, Jessica's performances continue to captivate audiences across film, television and stage. Acclaimed as one of the greatest actresses of her generation, Jessica is the 15th Oscar winner to appear on Girls On Film. The conversation was recorded on 1 March 2025. http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Alex Jones House band: MX Tyrants Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

As the organ transplant list continues to grow, experts in the transplant diagnostics industry are looking for ways to address the supply and demand challenges within the field. New tactics, like retransplantation and xenotransplantation, and new testing methods, such as HLA testing and transplant diagnostics, are being explored to boost transplant success rates and ensure more patients get the lifesaving transplants they need. As President of Thermo Fisher Scientific's transplant diagnostics division, Tina Liedtky is at the cutting edge of meeting this challenge. She's also passionate about addressing health equity issues, such as ingrained biases regarding gender and race, to help bridge the transplantation gap.Tina joined Meg for a fascinating discussion about the future of transplantation, closing 'the gap', and Thermo Fisher's recent award. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Í þættinum í dag ræða Söguskoðunarmenn um Markús Árelíus, keisara og heimspeking, sem stundum er kallaður síðasti gullaldarkeisari Rómaveldis. Stjórn hans markaði lok tímabils friðar og stöðugleika í ríkinu, en einnig upphaf hnignunar.Markús Árelíus var ekki aðeins valdamikill keisari heldur einnig hugsuður í anda stóuspekinnar. Í riti sínu, Hugleiðingar, sem ekki var ætlað til birtingar, speglar hann eigin siðferðisviðhorf, ábyrgð sína sem stjórnanda og viðleitni til að lifa í samræmi við náttúrulega reglu heimsins. Þrátt fyrir heimspekilega rósemi þurfti hann að leiða Rómarveldi í gegnum stríð við Parþa og Germani, og mikla drepsótt sem loks varð hans bani.Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

In this episode of Girls On Film, recorded at the 2025 Glasgow Film Festival, host Anna Smith is joined by co-founder and Executive Producer of the podcast, Hedda Lornie Archbold, to bring listeners exclusive interviews with some of the festival's stars. They welcome insights from Festival Director Allison Gardner, star of opening gala film Tornado, Kōki, and two of the creative minds behind The Extraordinary Miss Flower. Allison Gardner talks about her highlights of her final year leading the Glasgow Film Festival. Kōki, the rising star of Tornado, opens up about her role as the daughter of a Japanese puppeteer in John Maclean's thriller. And Emiliana Torrini and Caroline Catz dive into their work on The Extraordinary Miss Flower, a genre-blending love letter to love letters, set to Torrini's dreamy soundtrack. The Extraordinary Miss Flower will be released in the UK on 9 May 2025. Tornado will be available in cinemas from 23 May 2025. Glasgow Film Festival 2025 runs from 26 February to 9 March 2025. For more information on screenings and tickets, visit the Glasgow Film Festival website https://www.glasgowfilm.org/home March is International Women's Month, and this year also marks the 20th Anniversary of Birds Eye View Festival, now Reclaim the Frame, a charity championing women filmmakers. The festival will host a Weekender from 7–9 March 2025 at BFI Southbank and Regent Street Cinema, featuring events, screenings, and a special showing of Lollipop, which featured in episode 181 of Girls On Film. For more details, visit reclaimtheframe.org.Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Benjamin Cook House band: MX Tyrants Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

Host Anna Smith brings you an exclusive conversation with Zoe Saldaña, Clément Ducol and Camille, recorded live at London's Charlotte Street Hotel following a screening of the 13 time Oscar-nominated and 12 time BAFTA-nominated film Emilia Pérez. Directed by Jacques Audiard, this genre-blending musical thriller tells the story of a lawyer who becomes entangled in the world of a cartel boss undergoing a dramatic personal transformation. Starring Karla Sofía Gascón, Zoe Saldaña, Selena Gomez and Adriana Paz, the film is generating awards buzz for its bold storytelling and powerful performances. Joining Anna for this discussion is Oscar-nominee Zoe Saldaña, who plays Rita in the film. She shares her experience collaborating with versatile French filmmaker Jacques Audiard on bringing to life the story of four Latina women, citing how refreshing it was to embody a flawed woman, the character of Rita. She's joined by Clément Ducol and Camille, the composers and songwriters behind the film's evocative soundtrack, who share insights into the five-year-long creative process of bringing Emilia Pérez's distinctive musical identity to life. This episode was recorded live on 31 January 2025 and is brought to you in partnership with Netflix. Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Alex Jones Sound recordist: Erin Millican House band: MX Tyrants This episode is in partnership with Netflix © HLA Agency

In this special episode recorded at the 2025 Girls On Film Awards, we celebrate the remarkable achievements of women and people of marginalised genders in the film industry. Hosted by co-founders of Girls On Film Anna Smith and Hedda Lornie Archbold, the evening features inspiring speeches, awards across 14 categories, and interviews with some standout guests. You'll hear highlights from the ceremony, including insights from Oscar-nominated directors Coralie Fargeat (The Substance) and Shiori Itō (Black Box Diaries) as well as Oscar-nominated Actress Karla Sofía Gascón (Emilia Pérez). Also in this episode, attendees reflect on the importance of women-led cinema and diverse voices in the industry. We also spotlight the sponsors and partners who made the event possible: our Gold Sponsors, CrewHQ and IMDb; our Silver Sponsor, Curzon; and our Bronze Sponsors, Netflix and Intimacy on Set. We are grateful for the support of our media partners Deadline, British Cinematographer magazine, and DDA, and to Lilac Grove Entertainment for sponsoring the reception. The awards celebrate the ongoing progress toward more inclusive storytelling, and this episode brings you right into the heart of the celebration. This episode is sponsored by Elstree Film Studios, who are celebrating their centenary in 2025. Full list of winners BEST FEATURE FILM The Substance BEST DOCUMENTARY FEATURE Black Box Diaries BEST PERFORMANCE IN A LEADING ROLE Marianne Jean-Baptiste (Hard Truths) BEST PERFORMANCE IN A SUPPORTING ROLE Danielle Deadwyler (The Piano Lesson) FEMALE FRIENDSHIP ON SCREEN All We Imagine as Light ENSEMBLE CAST Emilia Pérez THE GIRLS ON FILM ALLY AWARD SPONSORED BY IMDb Mike Leigh (Hard Truths) BEST CINEMATOGRAPHY SPONSORED BY CREWHQ Hélène Louvart AFC (La Chimera) BEST PRODUCTION DESIGN Judy Becker (The Brutalist) BEST COSTUME DESIGN Linda Muir (Nosferatu) BEST COMPOSER Abigail Barlow and Emily Bear (Moana 2) BEST PUBLICITY CAMPAIGN Universal (Wicked) ACTIVIST IMPACT AWARD Shiori Ito (Black Box Diaries) FEMALE ORGASM ON SCREEN SPONSORED BY INTIMACY ON SET Nicole Kidman (with Nicole Kidman, and later Harris Dickinson) (Babygirl) Full list of commendations ENSEMBLE CAST Chuck Chuck Baby BEST COMPOSER Isobel Waller-Bridge (Wicked Little Letters) BEST PRODUCTION DESIGN Gemma Jackson (Lee) BEST COSTUME DESIGN Rebecca Gore (Timestalker) Find out more here https://hlaagency.co.uk/category/projects/girls-on-film-awards/ Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Interns: Anna Swartz and Oli Fyne Sound recordist: Erin Macmillan Audio editor: Benjamin Cook House band: MX Tyrants © HLA Agency

Madam President and all-around Immunogenetics boss, Dr. Cathi Murphey joins the podcast to discuss recent CMS updates, guidance, and clarifications on HLA testing and personnel.

Anna Smith takes a closer look at the poignant, BAFTA-nominated Netflix documentary Daughters, co-directed by Natalie Rae and Angela Patton. The film intimately portrays the lives of four young Black women in the United States, navigating the emotional challenges of growing up with fathers who are incarcerated. Directors Natalie and Angela join Anna to discuss their eight-year journey bringing this powerful story to life, from filming during the pandemic to building an open and compassionate dialogue with the young women seen on screen, all culminating in the transformative Daddy Daughter Dance at the heart of the documentary. Angela Patton, CEO of Girls For A Change, shares her perspective on amplifying young women's voices, while Natalie Rae delves into the creative and emotional process of filming such a personal and moving story in this episode of Girls On Film. Daughters is available to stream on Netflix now. Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Emma Butt House band: MX Tyrants This episode is in partnership with Netflix © HLA Agency

For more information, visit https://thecirsgroup.com CIRS, or Chronic Inflammatory Response Syndrome, is an illness usually caused by your genes. But there are two different genetic based tests you can get! One to determine your Genetic HLA Haplotype, and one to see what genes are up or down regulated. Both inform your treatment to varying degrees, so today we want to help you understand which does what and whether these tests make sense for you. For more information, support, and resources in your own CIRS healing journey, visit TheCIRSGroup.com TIME STAMPS: 0:00 Intro and disclaimer 1:05 The confusion between genetic haplotypes vs GENIE tests 2:00 HLA Genetic Haplotypes: what is that? 4:08 Why HLA testing is important 5:04 HLA does not change, and you'll probably need help to figure out what it is 6:42 Autoimmune genes vs CIRS genes 8:08 What is the GENIE test? 8:50 When should you get the GENIE test? 9:55 GENIE shows the expression of genes 11:30 What the GENIE can tell you 11:50 How to interpret your GENIE (hint: get help) 13:37 When and whether to test if you are tight on funds HELPFUL LINKS: Buy Jacie's book (and leave a review!): https://a.co/d/1uYwP0q The CIRS Summit: http://thecirssummit.com/ MyHouseMakesMeSick HLA calculator: https://www.myhousemakesmesick.com/hlacalc/ Our GENIE test episodes: https://youtu.be/bCNp9qNqWWc?si=Y0naeyaEGVUXYm5W https://youtu.be/OoiT7WZ_UJI?si=s6aUTNO3iLf9fKvQ Order the GENIE here: https://www.progenedx.com/product-index Book a consultation with Christian to interpret your GENIE: https://cirslab.circle.so/checkout/11-with-christian The CIRS Group: Join our support community: https://thecirsgroup.com Check out our instagram: https://www.instagram.com/thecirsgroup/ Find Jacie for carnivore, lifestyle and limbic resources: Instagram: https://www.instagram.com/ladycarnivory YouTube: https://www.youtube.com/@LadyCarnivory Blog: https://www.ladycarnivory.com/ Order Jacie's book! https://a.co/d/8ZKCqz0 Find Barbara for business/finance tips and coaching: Website: https://www.actlikebarbara.com/ Instagram: https://www.instagram.com/actlikebarbara/ YouTube: https://www.youtube.com/@actlikebarbara Jacie is a Shoemaker certified Proficiency Partner, NASM certified nutrition coach, author, and carnivore recipe developer determined to share the life changing information of carnivore and CIRS to anyone who will listen. Barbara is a business and fitness coach, CIRS and ADHD advocate, speaker, and a big fan of health and freedom. Together, they co-founded The CIRS Group, an online support community to help people that are struggling with their CIRS diagnosis and treatment.

In this episode, Julia, Mason, and the former program assistant, now Water Conservation Educator, Andrew discuss the future of water conservation education with OK County OSU Extension. They also discuss how the Oklahoma City Water Utilities Trust (OCWUT), Oklahoma Department of Environmental Quality (OK-DEQ), and the Oklahoma Water Resource Board (OWRB) manage water. Related Fact Sheets: AGEC-1018: "Understanding the Different Kinds of Water Addressed by Oklahoma's Water Law" CR-1016: "Economic Impact of Conservation Dollars in Oklahoma" WREC-1017: "Considering Water Quality in Oklahoma" WREC-104: "Introduction to Groundwater Hydrology and Management" L-346: "Responsible Lawn Care" L-458: "Water-Wise Landscape Principles for Oklahoma" HLA-6615: "Simple Irrigation Checkup for Home Sprinkler Systems" BAE-1511: "Drip Irrigation Systems" BAE-1757: "Design of Rainwater Harvesting Systems in Oklahoma" PSS-2902: "What Soil, Forage, or Water Test Do You Need?" HLA-6444: "Drought Tolerant Plant Selections for Oklahoma"

On this special holiday episode, Julia, Andrew, and Mason discuss the history, care, and legends on the poinsettia. Related fact sheets and articles: HLA-6413: Poinsettia Care Poinsettias are a long-time holiday favorite Care for poinsettias during the holiday season

In today's episode, we welcome back Dr. Amar Kelkar for part 1 of our two-part discussion on allogeneic transplant. In this episode, we discuss the fundamental approach to patient selection and stem cell source selection. As you all know from this series, allogeneic transplants play a pivotal role in the management of AML. Dr. Kelkar's pearls of wisdom help make this confusing topic so much more approachable!Episode contents: - What factors do we incorporate when considering a patient for allogeneic transplant? - How do we use HLA-matching?- What are the pros and cons of the different sources of stem cells? ****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this episode, host Anna Smith transports listeners to the world of Wicked. She speaks with three key creatives behind this enchanting film adaptation of the hit Broadway musical. Directed by Jon M. Chu, the film stars Cynthia Erivo as Elphaba and Ariana Grande as Glinda, bringing this iconic story of friendship, magic, and love to life on the big screen. Hair, Makeup, and Prosthetics Designer Frances Hannon discusses how she approached creating Elphaba's iconic green look. Director of Photography Alice Brooks explains how she updated the technicolour dreamworld of Oz through the film's cinematography. And, Costume Designer Paul Tazewell describes how he developed a ‘language of clothing' to reflect the world and characters of Oz. The episode highlights the significant role that Hair and Makeup Design, Costume Design and Cinematography play in bringing the story of these two complex women to life. Listeners will get a glimpse into the artistry behind the film and the collaborative effort that makes Wicked both visually stunning and emotionally resonant. Wicked is in UK cinemas now, with part two coming next year. Let us know what you think on social media - tag Girls On Film and use the hashtag #WickedMovie. Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Emma Butt House band: MX Tyrants This episode is in partnership with Universal Pictures © HLA Agency

In this live Fertility Expert Q and A , I'm joined by Dr. Andrea Vidali. I had the honor of interviewing him about Pregmune, a platform for patients to receive a Reproductive Immunology work-up with him. We dove into the 6 categories that are part of a reproductive immunology work-up: HLA testing, NK activity, Systemic Inflammation, Thrombophilia, Regulatory T-cell, and Autoimmunity. It was so fascinating to learn from the best today. I hope you will listen in! Read the full show notes on Dr. Aimee's website. Pregmune's website. Subscribe to my YouTube channel for more fertility tips! Subscribe to the newsletter to get updates Do you have questions about IVF?Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, December 16th, 2024 at 4pm PST (7pm EST), where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom. Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.

Girls On Film brings you a live recording from the BFI's Art of Action season at the Exeter Phoenix Cinema in Devon. Host Anna Smith is joined by Priya Kansara, star of the genre-blending feminist action film Polite Society. Following a screening of Nida Manzoor's 2023 film, Priya discusses her lead role as Ria, a spirited young martial artist determined to stop her sister's wedding with an audacious heist. She describes how, despite their different heritages, she instantly identified with the character of Ria, and revealed how she worked with Manzoor to put a personal spin on the film's more comedic scenes. Priya also discusses the reality of finding a stunt double when you're a brown girl, calling for change in this area of the industry, as well as sharing some top tips for film industry newcomers to battle imposter syndrome. Listen to hear more! The conversation includes a post-screening Q&A with audience questions. This episode is part of Art of Action: Smash the Glass, a season that celebrates the women who have advanced action cinema both on and off-screen. The season is supported by National Lottery and BFI Film Audience Network with generous sponsorship from Packexe. To find out more about the BFI's Art of Action season, and, for our UK listeners, to see which films are screening near you, visit the British Film Institute website below. The season is running from October to December 2024. https://www.bfi.org.uk/art-action Also in this week's episode, Girls On Film is delighted to be celebrating our sixth birthday with the Female Film Club - a global members' club specifically for women in film - who are turning four. Together we share 10 years in the industry, and to mark the occasion Female Film Club are opening up their networking space to Girls On Film listeners who work the film industry: They offer a completely free networking space designed to help you make meaningful connections within the industry and to network with other members. With thousands of members in their database, you'll be joining a supportive community of creatives worldwide. With free membership, you'll get access to the FFC app, direct messaging with fellow members, and exclusive perks like special events and industry opportunities. It's a fantastic way to grow your network, build your skills, and get real support—some members have even landed jobs through it! https://female-film-club.mn.co/sign_up?bundle_token=e2f89f5961bbb9100aff796e6b36e50c&plan_id=479915&utm_source=manual” Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Benjamin Cook House band: MX Tyrants © HLA Agency

Nú um hegina kom út sex þátta röð frá einu þekktasta og virtasta hlaðvarpsfyrirtæki heims Serial, sem er hluti af New York Times fjölmiðlasamsteypunni. The Good whale sem fjallar um háhyrninginn Keikó. Hlaðvarpsþættirnir rekja sögu Keikós sem varð að alþjóðlegu tákni um illa meðferð á háhyrningum og hvölum almennt þegar hann lék í Hollywood-kvikmyndinni Free Willy árið 1993. Þá bjó hann i skemmtigarði í Mexíkó þar sem hann naut mikilla vinsælda en bjó við þröngan kost og slæma heilsu. Sú brjálæðislega hugmynd kviknaði að láta lífið líkja eftir listinni og reyna að koma dýrinu aftur út í náttúruna, gera húsdýrið villt aftur. Framkvæmdin var gríðarlega flókin, rándýr og umdeild. Keikó var fyrst fluttur til Oregon í Bandaríkjunum í hálfgerða endurhæfingu, og svo til Vestmannaeyja í september árið 1998. Í Lestinni í dag ætlum við að ræða við einn helsta þjálfara og umönnunaraðila Keikós á síðustu æviárum hans, Þorbjörgu Valdísi Kristjánsdóttur.

https://solvitryggva.is/ Vinirnir Helgi Jean Claessen og Hjálmar Örn Jóhannsson hafa í áraraðir verið að gera grínefni saman, en á löngum köflum gekk það brösulega. Hjálmar fór að vinna á leikskóla og Helgi fór í jakkaföt og vildi verða bissnessmaður. En dropinn holar steininn og í dag eru þeir í fullri vinnu við að gera grínefni, bæði í Hlaðvarpinu Hæhæ og Hjálmar fer í gervi Hvítvínskonunnar nær daglega. Hér ræða þeir Sölvi um mikilvægi þess að elta draumana, gefast ekki upp, hætta að láta álit annarra stýra sér og margt margt fleira. Þátturinn er í boði; Narfeyrarstofa - https://narfeyrarstofa.is/ Caveman - https://www.caveman.global/ H-Berg - https://hberg.is/ Nings - https://nings.is/ Myntkaup - https://myntkaup.is

In this special episode from the Evolution Mallorca International Film Festival, Anna Smith hosts a panel discussion on women in leadership within the film industry. In the third iteration of this panel, Anna is joined by three international industry leaders: Kirsty Bell, CEO of the Oscar-winning production company Goldfinch, international film publicity strategist Mia Farrell and Oscar-nominated producer Rebecca Pruzan. Together, they explore the pathways to landing leadership roles, the skills needed to thrive once there, and the shifting dynamics of gender and race in the film industry. Kirsty Bell shares her experiences starting Goldfinch as a family business and reflects on directing A Bird Flew In—the first film shot during the pandemic, which pioneered COVID protocols on set. She also highlights the importance of supportive men in her life, and how they've played a role in her career. Mia Farrell offers insights from her career as a publicist, discussing her passion for elevating films through strategic PR, as well as her advocacy for greater diversity in the industry. She tells the audience about the genesis of her impactful Screen Daily article, "Why are so few Black people in positions of power in the arthouse film PR sector?'”. Mia also shares her experiences working on The Dads, a heartfelt documentary on fatherhood and trans youth, directed by Luschina Fisher, and available on Netflix. Rebecca Pruzan discusses her transition from a career in IT and consultancy to becoming an Oscar-nominated producer. She reflects on the identity politics at play in producing her short film IVALU, highlighting the challenges of navigating cultural sensitivities in storytelling and discussing the reaction to the film on its festival journey. This episode is in partnership with Evolution Mallorca International Film Festival. You can find out more about the Evolution Mallorca International Film Festival here: https://www.evolutionfilmfestival.com/tickets A reminder that you can read a transcript of our episodes on Apple Podcasts by clicking the ‘transcript' option in settings in the episode description. Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.x.com/GirlsOnFilm_Pod www.x/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Benjamin Cook House band: MX Tyrants © HLA Agency

Dr. Ryan Augustin and Dr. Jason Luke discuss neoadjuvant immunotherapy and the importance of multidisciplinary team coordination, promising new TIL therapy for advanced melanoma, and the emerging role of CD3 engagers in treatment strategies. TRANSCRIPT Dr. Ryan Augustin: Hello, I'm Dr. Ryan Augustin, your guest host of the ASCO Daily News Podcast today. I'm a medical oncology fellow at Mayo Clinic in Rochester, Minnesota. Joining me today is Dr. Jason Luke, an associate professor of medicine and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh Hillman Cancer Center. I had the privilege of working as a postdoc in Jason's translational bioinformatics lab, where we investigated mechanisms of resistance to immunotherapy in melanoma and other cancers.  Today, we'll be discussing 3 important topics, including neoadjuvant immunotherapy and the importance of multidisciplinary team coordination, the impact and practical considerations for incorporating TIL therapy into melanoma, and the current and future use of CD3 engagers in both uveal and cutaneous melanoma.  You'll find our full disclosures in the transcript of this episode.  Jason, it's great to have this opportunity to speak with you today. Dr. Jason Luke: Absolutely. Thanks, Ryan. It's great to see you. Dr. Ryan Augustin: So, to kick things off, Jason, we, of course, have seen tremendous advances in cancer immunotherapy, not only in metastatic disease but also the perioperative setting. Recent data have shown that the use of neoadjuvant therapy can provide not only critical prognostic information but can also help individualize post-resection treatment strategies and potentially even eliminate adjuvant therapy altogether in patients who achieve a pathologic, complete response. This signifies a conceptual shift in oncology with the goal of curing patients with immunotherapy. In triple-negative breast cancer, the KEYNOTE-522 regimen with pembrolizumab is standard of care. In non-small cell lung cancer, there are now four FDA approved chemo-IO regimens in both the neoadjuvant and perioperative settings. And, of course, in melanoma, starting with SWOG S1801 utilizing pembro mono therapy, and now with combined CTLA-4 PD-1 blockade based on results from the NADINA trial, neoadjuvant IO is the new standard of care in high-risk, resectable melanoma. It's important to highlight this because whereas other tumor types have more mature multidisciplinary care, for example, patients with breast cancer are reviewed by the whole team in every center, and every patient with lung cancer certainly benefits from multidisciplinary care conferences, that's not always the case with melanoma, given the relative frequency of cases compared to other tumor types.  Jason, would you say that we have now moved into an era where the integration of a multidisciplinary team and melanoma needs to be prioritized. And why is it important to have multidisciplinary team coordination from the onset of a patient's diagnosis? Dr. Jason Luke: Well, I think those are great questions, Ryan, and I think they really speak to the movement in our field and the great success that we've had integrating systemic therapy, particularly immunotherapy, into our treatment paradigms. And so, before answering your question directly, I would add even a little bit more color, which is to note that over the last few years, we've additionally seen the development of adjuvant therapy into stages of melanoma that, historically speaking, were considered low-risk, and medical oncologists might not even see the patient. To that, I'm speaking specifically about the stage 2B and 2C approvals for adjuvant anti-PD-1 with pembrolizumab or nivolumab. So this has been an emerging complication.  Classically, patients are diagnosed with melanoma by either their primary care doctor or a dermatologist. Again, classically, the next step was referral to a surgeon who had removed the primary lesion, with discussion around nodal evaluation as well. And that paradigm has really changed now, where I think integration of medical oncology input early on in the evaluation of the appropriate treatment plan for patients with melanoma is quite a pressing issue now, both because we have FDA approvals for therapeutics that can reduce risk of recurrence, and whether or not to pursue those makes a big difference to the patient for discussion early on.  And, moreover, the use of systemic therapies now, prior to surgery, of course, then, of course, requires the involvement of medical oncology. And just for an emphasis point on this, it's classically the case, for good reason, that surgeons complete their surgery and then feel confident to tell the patient, “Well, we got it all, and you're just in really good shape.” And while I understand where that's coming from, that often leaves aside the risk of recurrence. So you can have the most perfect surgery in the world and yet still be at very high risk of recurrence. And so it's commonly the case that we get patients referred to us after surgery who think they're just in totally good shape, quite surprised to find out that, in fact, they might have a 20% to 50% risk of recurrence. And so that's where this multidisciplinary integration for patient management really does make a big difference.  And so I would really emphasize the point you were making before, which is that we need multidisciplinary teams of med onc with derm, with surgery early on, to discuss “What are the treatment plans going to be for patients?” And that's true for neoadjuvant therapy, so, for palpable stage 3, where we might give checkpoint inhibitors or combinations before surgery. But it's true even in any reasonably high-risk melanoma, and I would argue in that state, anything more than stage 1 should be discussed as a group, because that communication strategy with the patient is so important from first principles, so that they have an expectation of what it's going to look like as they are followed out over time. And so we're emphasizing this point because I think it's mostly the case at most hospitals that there isn't a cutaneous oncology disease management meeting, and I think there needs to be.  It's important to point out that usually the surgeons that do this kind of surgery are actually either the GI surgeons who do colon cancer or the breast surgeons. And so, given that melanoma, it's not the most common kind of cancer, it could easily be integrated into the existing disease review groups to review these cases. And I think that's the point we really want to emphasize now. I think we're not going to belabor the data so much, but there are enormous advantages to either perioperative or adjuvant systemic therapy in melanoma. We're talking about risk reduction of more than 50%, 50-75% risk reduction. It's essential that we make sure we optimally offer that to patients. And, of course, patients will choose what they think is best for their care. But we need to message to them in a way that they can understand what the risks and benefits of those treatments are and then are well set up to understand what that treatment might look like and what their expectations would be out over time.  So I think this is a great art of medicine place to start. Instead of belaboring just the details of the trial to say, let's think about how we take care of our patients and how we communicate with them on first principles so that we can make the most out of the treatments that we do have available. Dr. Ryan Augustin: That's great, Jason. Very insightful points. Thank you.  So, shifting gears now, I'd also like to ask you a little bit about TIL therapy in melanoma. So our listeners will be aware that TIL is a promising new approach for treating advanced melanoma and leverages the power of a patient's cytotoxic T cells to attack cancer cells. While we've known about the potential of this therapy for some time, based on pioneering work at the NCI, this therapy is now FDA approved under the brand AMTAGVI (Lifileucel) from Iovance Biotherapeutics, making it the first cellular therapy to be approved for a solid tumor. Now, I know TIL therapy has been administered at your institution, Jason, for several years now, under trial status primarily for uveal melanoma using an in-house processing. But for many cancer centers, the only experience with cellular therapy has come under the domain of malignant hematology with CAR T administration. At our institution, for example, we have only recently started administering TIL therapy for melanoma, which has required a tremendous multidisciplinary effort among outpatient oncology, critical care, and an inpatient hematology service that has expertise in cytokine release syndrome.  Jason, where do you see TIL therapy fitting into the metastatic space? Which patients do you think are truly candidates for this intensive therapy? And what other practical or logistical considerations do you think we should keep in mind moving forward? Dr. Jason Luke: Well, thanks for raising this. I think the approval of lifileucel, which is the scientific name for the TIL product that's on the market now. It really is a shift, a landscape shift in oncology, and we're starting in melanoma again, as seems to be commonly the case in drug development. But it's really important to understand that this is a conceptually different kind of treatment, and therefore, it does require different considerations. Starting first with data and then actualization, maybe secondarily, when we see across the accelerated approval package that led to this being available, we quote patients that the response rate is likely in the range of 30%, maybe slightly lower than that, but a meaningful 25% to 30% response rate, and that most of those patients that do have response, it seems to be quite durable, meaning patients have been followed up to four years, and almost all the responders are still in response. And that's a really powerful thing to be able to tell a patient, particularly if the patient has already proceeded through multiple lines of prior standard therapy. So this is a very, very promising therapy.  Now, it is a complicated therapy as well. And so you highlighted that to do this, you have to have a tumor that's amenable for resection, a multidisciplinary team that has done a surgery to remove the tumor, sent it off to the company. They then need to process the TIL out of the tumor and then build them up into a personalized cell product, bring it back, you have to lympho-deplete the patient, re-introduce this TIL. So this is a process that, in the standard of care setting under best circumstances, takes roughly six weeks. So how to get that done in a timely fashion, I think, is evolving within our paradigms. But I think it is very important for people who practice in settings where this isn't already available to realize that referring patients for this should be a strong consideration. And thinking about how you could build your multidisciplinary team in a way to be able to facilitate this process, I think is going to be important, because this concept of TIL is relevant to other solid tumors as well. It's not approved yet in others, but we kind of assume eventually it probably will be. And so I think, thinking through this, how could it work, how do you refer patients is very important.  Now, coming back to the science, who should we treat with this? Well, of course, it's now an air quotes “standard of care option”, so really it ought to be available to anybody. I will note that currently, the capacity across the country to make these products is not really adequate to treat all the patients that we'd want. But who would we optimally want to treat, of course, would be people who have retained a good performance status after first line therapy, people who have tumors that are easily removable and who have not manifested a really rapid disease progression course, because then, of course, that six-week timeline probably doesn't make sense. The other really interesting data point out of the clinical trials so far is it has looked like the patients who got the least amount of benefit from anti-PD-1 immunotherapy, in other words, who progressed immediately without any kind of sustained response, those patients seem to have the best response to TILs, and that's actually sort of a great biomarker. So, this drug works the best for the population of patients where checkpoint inhibitors were not effective. And so as you think about who those patients might be in your practice, as you're listening, I think prioritizing it for primary progression on anti PD-1, again and giving it ahead thought about how would you get the patient through this process or referred to this process very quickly is really important because that lag time is a problem. Patients who have melanoma tend to progress reasonably quickly, and six weeks can be a long time in melanoma land. So, thinking ahead and building those processes is going to be important moving into the future Dr. Ryan Augustin: Definitely appreciate those practical considerations. Jason, thank you.  Moving on to our final topic, I was hoping to discuss the use of immune cell engagers in melanoma. So, similar to CAR T therapy, bispecific T-cell engagers, or BiTEs, as they're commonly known, are standard of care in refractory myeloma and lymphoma. But these antibodies engaging CD-3 on T cells and a tumor specific antigen on cancer cells are relatively new in the solid tumor space. Tarlatamab, which is a DLL-3 and CD-3 bispecific antibody, was recently approved in refractory small cell lung cancer, and, of course, tebentafusp, an HLA-directed CD-3 T cell engager was approved in uveal melanoma in 2022. Both T and NK cell engaging therapies are now offering hope in cancers where there has historically been little to offer. However, similar to our discussion with TIL therapy, bispecifics can lead to CRS and neurotoxicity, which require considerable logistical support and care coordination.  Jason, I was wondering if you could briefly discuss the current landscape of immune cell engagers in melanoma and how soon we may see these therapies enter the treatment paradigm for cutaneous disease. Dr. Jason Luke: I think it is an exciting, novel treatment strategy that I think we will only see emerge more and more. You alluded to the approval of tebentafusp in uveal melanoma, and those trials were, over the course of a decade, where those of us in solid tumor land learned how to manage cytokine release syndrome or the impact of these C3 bispecifics, in a way that we weren't used to. And what I'll caution people is that CRS, as this term, it sounds very scary because people have heard of patients that, of course, had difficult outcomes and hematological malignancies, but it's a spectrum of side effects. And so, when we think about tebentafusp, which is the approved molecule, really what we see is a lot of rash because GP100, the other tumor antigen target, is in the skin. So, patients get a rash, and then people do get fevers, but it's pretty rare to get more than that. So really what you have to have is the capacity to monitor patients for 12 hours, but it's really not more scary than that. So it really just requires treating a few people to kind of get used to these kinds of symptoms, because they're not the full-on ICU level CRS that we see with, say, CAR T-cells.  But where is the field going? Well, there's a second CD3 bispecific called brenetafusp that targets the molecule PRAME, that's in a phase 3 clinical trial now for frontline cutaneous melanoma. And tebentafusp is also being evaluated in cutaneous melanoma for refractory disease. So, it's very possible that these could be very commonly used for cutaneous melanoma, moving into, say, a two-to-four-year time horizon. And so therefore, getting used to what are these side effects, how do you manage them in an ambulatory practice for solid tumor, etc., is going to be something everyone's going to have to learn how to deal with, but I don't think it should be something that people should be afraid of.  One thing that we've seen with these molecules so far is that their kinetics of treatment effect do look slightly different than what we see with more classic oncology therapies. These drugs have a long-term benefit but doesn't always manifest as disease regression. So, we commonly see patients will have stable disease, meaning their tumor stops growing, but we don't see that it shrank a lot, but that can turn into a very meaningful long-term benefit. So that's something that we're also, as a community, going to have to get used to. It may not be the case we see tumors shrink dramatically upfront, but rather we can actually follow people with good quality- of-life over a longer period of time.  Where is the field going? You mentioned tarlatamab in small cell lung cancer, and I think we're only going to see more of these as appropriate tumor antigens are identified in different tumors. And then the other piece is these CD3 engagers generally rely upon some kind of engagement with a T cell, whether CD3 engagers, and so they can be TCR or T-cell receptor-based therapies, although they can be also SCFV-based. But that then requires new biomarkers, because TCR therapy requires HLA restriction. So, understanding that now we're going to need to profile patients based on their germline in addition to the genomics of the tumor. And those two things are separate. But I would argue at this point, basically everybody with cutaneous melanoma should be being profiled for HLA-A(*)0201, which is the major T-cell receptor HLA haplotype that we would be looking for, because whether or not you can get access immediately to tebentafusp, but therefore clinical trials will become more and more important.  Finally, in that T-cell receptor vein, there are also T cell receptor-transduced T cells, which are also becoming of relevance in the oncology community and people listening will be aware in synovial sarcoma of the first approval for a TCR-transduced T cell with afamitresgene autoleucel. And in melanoma, we similarly have TCR-transduced T cells that are coming forward in clinical trials into phase 3, the IMA203 PRAME-directed molecule particularly. And leveraging our prior conversation about TILs, we're going to have more and more cellular based therapies coming forward, which is going to make it important to understand what are the biomarkers that go with those, what are the side effect profiles of these, and how do you build your practice in a way that you can optimally get your patients access to all of these different treatments, because it will become more logistically complicated, kind of as more of these therapies come online over the next, like we said, two to four years kind of time horizon. So, it's very exciting, but there is more to do, both logistically and scientifically. Dr. Ryan Augustin: That's excellent. Thanks, Jason, and thank you so much for sharing your great insight with us today on the ASCO Daily News Podcast. Dr. Jason Luke: Thanks so much for the opportunity. Dr. Ryan Augustin: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode, and you can follow Dr. Luke on X, formerly known as Twitter, @jasonlukemd. And you can find me, @RyanAugustinMD. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers: @ryanaugustinmd Dr. Jason Luke @jasonlukemd   Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures: Dr. Ryan Augustin: No relationships to disclose Dr. Jason Luke: Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof) Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

In this JCO Article Insights episode, Alexandra Rojek provides a summary on "Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors" by Schaffer et al published in the Journal of Clinical Oncology July 17th, 2024. TRANSCRIPT Alexandra Rojek: Hello and welcome to JCO Article Insights. I'm your host, Alexandra Rojek, and today we will be discussing an original report published in the October 1st issue of JCO titled, “Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors,” by Shaffer et al. The CIBMTR registry study set out to compare outcomes of patients undergoing allogeneic stem cell transplantation hematologic malignancies by HLA antigen matching status as well as by the type of GVHD prophylaxis regimen received either calcineurin inhibitor-based prophylaxis or post-transplant cyclophosphamide or PTCy. This study included patients reported to CIBMTR from January 2017 to June 2021 with AML, ALL or MDS, and required that they have undergone allotransplant with either a calcineurin inhibitor based so tacro or cyclosporine, GVHD prophylaxis, or PTCy, which included a calcineurin inhibitor or sirolimus with or without MMF and ATG. Matched unrelated donors were defined as an 8 out of 8 HLA match. And mismatched unrelated donors were defined as HLA mismatched at any single locus or 7 out of 8. The primary objective of the study aimed to compare overall survival or OS and GVHD and relapse-free survival (GRFS) within and between matched unrelated donors versus mismatched unrelated donors separated by calcineurin inhibitor versus PTCy based GVHD prophylaxis. GRFS was defined as survival without grade 3 to 4 acute GVHD, moderate to severe chronic GVHD requiring systemic therapy or relapse. 10,025 patients were included from 153 centers, with a median follow up of over 36 months. Mismatched unrelated donor recipients were made up of 22% minority ancestry patients as compared to just 8% of patients receiving a matched unrelated donor allo transplant, showing an enrichment for patients of minority ancestry in the mismatched unrelated donor group. Just under 10% of patients were of minority ancestry in the study overall, reflective of challenges in transplant care for these patients, which may include inferior access to care, fewer available and suitably matched donors, among other factors. 54% of all patients were transplanted for AML and 29% for MDS. 45% of patients received myeloablative conditioning, 25% received regimens containing ATG, and 23% overall received PTCy with either a calcineurin inhibitor or sirolimus as well as MMF. Among patients receiving PTCy, the authors did not find differences in overall survival by degree of HLA matching, whereas among patients receiving calcineurin inhibitor-based prophylaxis, there remained survival differences by HLA matching status. When comparing matched unrelated donor calcineurin inhibitor patients with PTCy matched unrelated donor patients, the PTCy arm had better OS, and the mismatched unrelated donor group who received PTCy had similar OS as well. For GRFS, matched unrelated donor and mismatched unrelated donor PTCy patients had no difference in GRFS, similar to the trend the authors see with overall survival. But these patients also had better GRFS than matched unrelated donor patients receiving calcineurin inhibitor-based prophylaxis. Within each prophylaxis arm, there was no difference in GRFS by HLA matching status. HLA mismatched patients receiving PTCy were less likely to experience GRFS than HLA mismatched patients receiving calcineurin inhibitor-based prophylaxis. The authors saw similar differences in comparative trends when subgrouping patients based on conditioning intensity and additionally did not find differences in GRFS and OS by ATG exposure. When looking at patients with minority ancestry, those patients who received a match unrelated donor or mismatched unrelated donor with PTCy had comparable outcomes to non-Hispanic white patients. Additionally, among minority ancestry patients, there was a significant benefit in both GRFS and OS in the PTCy groups as compared to calcineurin inhibitor-based prophylaxis. When examining other specific toxicities included in the composite GRFS endpoint, such as GVHD rates among PTCy patients, the authors note that patients receiving a matched unrelated donor had similar rates of grade 3 to 4 acute GVHD but lower rates of moderate to severe chronic GVHD requiring systemic therapy. There appears to be signal that among PTCy patients, HLA matching reduced rates of moderate to severe chronic GVHD compared to mismatched unrelated donor patients receiving PTCy. These same trends also held when the authors looked at non relapse mortality with no significant differences within the PTCy groups by HLA matching status but reduced non relapse mortality compared to both calcineur and inhibitor-based groups. However, notably, there was a greater risk of relapse among matched unrelated donor PTCy patients than matched unrelated donor calcineurin inhibitor patients, although this risk was comparable between mismatched unrelated donor patients by type of prophylaxis. The authors note that this has also been observed in other retrospective cohorts and may be confounded by differences in conditioning intensity between these cohorts of matched unrelated donor patients, affecting the risk of relapse. Finally, the authors also evaluate whether expansion of donor search criteria to mismatch donors from full HLA matching would increase availability of young donors from minority ancestry patients, and the study noted striking increases for all subgroups examined. This study fits nicely with the BMT CTN 1703 trial published in the recent past, which has showed the superiority of PTCy with the calcineurin inhibitor and MMF when compared with conventional calcineurin inhibitor based immune prophylaxis for reduced intensity matched related donor and matched unrelated donor allotransplant. Of note, very few patients with one HLA antigen mismatch were enrolled on that study. However, others have shown the feasibility of PTCy in the mismatched unrelated donor setting, which has led to its adoption in practice. Although less than a quarter of patients included in this current study received PTCy overall, the findings clearly are aligned with the BMT CTN 1703 study, which is likely to change clinical practice in the longer term in this field. As the accompanying editorial in JCO, written by Dr. Chakravarty nicely lays out, the differences between this study and the EBMT registry study, also published in this issue of JCO are subtle but worthy of note. While both studies show that mismatched unrelated donor patients had worse OS and GRFS than those receiving matched unrelated donor transplants, and then among matched unrelated donor patients the addition of PTCy improved GRFS and OS, there is discordance between the studies whether the addition of PTCy abrogates the effect of HLA mismatching on GRFS and OS. As this editorial points out, there are strikingly different rates of T cell depletion with ATG between the US and Europe, which may account for differences in comparator arms that lead to this discordance. There are several very exciting clinical trials ongoing that will aim to answer some of these outstanding questions regarding comparisons of PTCy and T cell depletion, which the field eagerly looks forward to reviewing. In summary, this registry study of patients receiving allo transplant with matched unrelated donor or mismatched unrelated donor and calcineurin inhibitor or PTCy based GVHD prophylaxis, most notably shows that for patients who may not have a matched unrelated donor available, the addition of PTCy to a mismatched unrelated donor allo transplant allows for improved outcomes after transplant in toxicities and survival. This is most significant for patients of minority ancestries who usually have fewer matched unrelated donors available in registry searches. Improving the transplant options available to these groups of patients is of critical importance in improving equitable access to care for all of our patients. And this study, although retrospective in nature, provides an important understanding of our progress to date and suggests directions for future investigation may indeed be very feasible to continue to close these gaps in care for patients in need of an allo transplant for hematologic malignancies. This is Alexandra Rojek. Thank you for listening to JCO Article Insights. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

 Hal Gill from Preds Radio Network joins the show to talk Preds. Hal previewed tomorrow night's game against the Blackhawks. Hla also shared his thoughts on the new call-up Zach L'Heureux. Listen to hear more.

Framtíð Åge Fridtjof Hareide, lokaleikirnir í Bestu, enski og KFA tíminn gerður upp. Hlaðvarpsstjórnandinn Mikael lætur gamminn geisa, umsjón hafa Helgi Fannar og Keli.

In this festival special, Anna Smith island hops across some of the most unique film festivals of the season, taking listeners from Sea Change festival in Scotland's Tiree to the London Film Festival before ending in Mallorca to hear about the upcoming Evolution Mallorca International Film Festival 2024. First, Anna reports from this year's Sea Change Film Festival in the Inner Hebrides. She speaks with filmmaker Jeanie Finlay (Your Fat Friend, Seahorse) and festival-goers like Reclaim The Frame's Melanie Iredale about their time at Scotland's only annual festival dedicated to powering women in film. Next, she heads to the BFI London Film Festival to meet actor Deba Hekmat and writer Helen Simmons, whose film Last Swim has its premiere at this year's festival. This coming of age drama tells the story of Ziba, a young woman who celebrates her A-Level results with friends while grappling with a personal secret. With Anna, Deba discusses the authenticity of the film's dialogue, how it captured Gen Z sensibilities almost perfectly, and how she resonated with the character of Ziba. Helen reflects on working with a translator to capture an authentic Farsi that is spoken by Ziba and her mother in Last Swim, as well as speaking about the lack of representation of driven and intelligent young women in film. Anna also catches up with some friends of the podcast when she is out and about at LFF. Finally, it's off to Spain for a preview of the Evolution Mallorca International Film Festival. Anna sits down with festival director Sandra Lipski to discuss some of her feminist festival highlights. Sandra gives us an insight into the 2024 lineup, including the festival's plan to welcome five time Academy Award-nominee Annette Bening to Mallorca's sunny shores. Films Mentioned: Last Swim (2024) Black Box Diaries (2024) Anora (2024) Conclave (2024) All We Imagine As Light (2024) Twiggy (2024) The Extraordinary Miss Flower (2024) Las chicas de la estación (2024) The Grifters (1990) The Outrun (2024) Endurance (2024) Emilia Perez (2024) Your Fat Friend (2023) Widow Clicquot (2024) Hoard (2024) Principal Partners: Vanessa Smith and Peter Brewer Our partners for this episode: Evolution Mallorca International Film Festival You can buy tickets for Evolution Mallorca International Film Festival from the 17th October 2024 via this link: https://www.evolutionfilmfestival.com/tickets Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.x.com/GirlsOnFilm_Pod www.x/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Benjamin Cook House band: MX Tyrants © HLA Agency

Núna tel ég réttast að kveðja formlega hlaðvarpið Karlmennskan. Reyndar munu bakhjarlar sjá til þess að það verði áfram opið og aðgengilegt en ég mun ekki taka upp fleiri þætti. Það hefur verið afskaplega gaman að hitta og spjalla við svo margt frótt fólk með áhugaverða reynslu eða sjónarhorn á samfélagið. Markmiðið var alltaf að varpa ljósi á virkni feðraveldis í gegnum mismunandi birtingamyndir, sem höfðu einhvern snertiflöt við karla eða karlmennsku. Veit að það tókst oft vel upp. Og það gleður mig að vita að ennþá eru nokkur hundruð einstaklingar að hlusta á gamla þætti. Takk öll sem hlustuðuð. Takk öll sem gáfu tíma ykkar, reynslu og þekkingu í hlaðvarpinu.   P.S. Þau ykkar sem þráið meira af svipuðu efni getið gerst áskrifendur að vikulega hlaðvarpinu Sópað undan teppinu með Þorsteini V. og Huldu Tölgyes. Hlaðvarpið er að finna á þriðja.is

HLA Director and Transfusion Medicine Specialist, Dr. Ryan Pena, joins Coffee & Compatibility to discuss how HLA laboratories can support transfusion medicine specialists. From HLA typing to anti-HLA antibody analysis in this niche service, Dr. Pena breaks it all down.

Why You Should Listen:  In this episode, you will learn about the use of GENIE testing in Chronic Inflammatory Response Syndrome. About My Guest: My guest for this episode is Dr. Ritchie Shoemaker.  Ritchie Shoemaker, MD is a recognized leader in patient care, research, and an education pioneer in the field of biotoxin related illness.  While illness acquired following exposure to the interior environment of water-damaged buildings (WDB) comprises the bulk of Dr. Shoemaker's daily practice, other illnesses caused by exposure to biologically-produced toxins are quite similar in their “final common pathway.”  What this means is that while the illness might begin acutely with exposure to fungi, spirochetes, apicomplexans, dinoflagellates and cyanobacteria, for example, in its chronic form, each of these illnesses has similar symptoms, lab findings, and Visual Contrast Sensitivity (VCS) findings.  Taken together the inflammatory illness from each of these diverse sources is known as  Chronic Inflammatory Response Syndrome. Key Takeaways: What is GENIE? Is HLA-DR still relevant? What are the common triggers of CIRS?  Actinobacteria?  Endotoxins?  Mold and mycotoxins? What is hypometabolism? How does CIRS impact insulin and blood sugar? What is apoptosis? What is the role of coagulation in CIRS? Are upregulated cytokines seen in CIRS? Can GENIE identify those that may have Lyme? What are defensins? What is Ikaros? What is the role of MAP kinases in CIRS? What do Toll receptors tell us? How are B and T cells involved in CIRS? How many CIRS markers are needed in GENIE to suggest CIRS? What is the PTSD gene? How often is histamine involved? What are the cytoskeleton and microtubules?  What can be determined around the function of Treg cells? What are the recent additions to GENIE in the realm of Parkinson's disease? What has GENIE told us about MARCoNS? Connect With My Guest:  http://SurvivingMold.com Interview Date: September 11, 2024 Transcript: To review a transcript of this show, visit https://BetterHealthGuy.com/Episode205. Additional Information: To learn more, visit https://BetterHealthGuy.com. Disclaimer:  The content of this show is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing in today's discussion is meant to serve as medical advice or as information to facilitate self-treatment. As always, please discuss any potential health-related decisions with your own personal medical authority. 

In this CLASSIC episode of the Ruthlessly Aggressive Podcast, to get ready for the 2003 edition of Unforgiven, Jake Williams is joined by Scott Shifflet to discuss Unforgiven 2002. The duo discuss a fun eight man opener, Flair getting fooled by Jericho, Three Minute Warning's in ring debut, a disappointing performance from Van Dam and Triple H, Bischoff's HLA plans getting foiled, the Lesnar/Undertaker showdown, and much more. Follow along through this progression through aggression!

Dr. Gerald Morris, the current Chair of the OPTN Histocompatibility Committee, joins Coffee & Compatibility to discuss upcoming changes in HLA testing and nomenclature, and their potential impacts on organ allocation in the United States.

In this episode, we dive into the critical role of HLA gene variants, such as HLA-DRB1, and their profound impact on immune system function, particularly focusing on their significance in conditions like Lyme disease and mold toxicity. We'll explore how variations in these HLA genes, like the HLA-DRB1*0401 allele, influence the body's ability to recognize and respond to pathogens, potentially leading to chronic symptoms. The discussion will also cover HLA gene variant testing and how it can lend insight when it comes to taking a bioindividual approach to supporting the immune system. Topics: 1. Introduction - Explanation of HLA gene variants - Importance of HLA genes in immune system function 2. Basics of Genetics and Immunology - What is a chromosome? - Introduction to genes and their functions - Overview of DNA and protein synthesis 3. Major Histocompatibility Complex (MHC) - Description of the Major Histocompatibility Complex - Division of MHC genes into Class I, II, and III - Role of Class I MHC genes in antigen presentation - Role of Class II MHC genes in antigen presentation - Function of Class III MHC genes 4. HLA Genes and Immune Function - Explanation of Human Leukocyte Antigen (HLA) genes - Connection between MHC genes and HLA genes (human MHC) - Transcription and regulation of HLA genes - Response to internal and external signals - Role of Antigen-presenting cells (APCs) 5. Pathogen Recognition and Immune Activation - Mechanism of pathogen recognition by HLA genes - Activation of immune response by antigen presentation - Formation and function of peptide-HLA complexes 6. Impact of HLA Variants on Disease - Specific focus on Lyme disease and mold toxicity - Role of HLA Class II alleles in immune response - Association of HLA-DR alleles with chronic Lyme disease - Sensitivity to mold exposure linked to certain HLA gene variants 7. Testing and Implications of HLA Gene Variants - Importance of HLA gene variant testing - Broader implications for diseases like lupus and multiple sclerosis - Personalized approaches based on HLA gene variants 8. Biotoxin Illness and Poor Antigen Presentation Due to an HLA Gene Variant - Strategies to support immune system function in the presence of biotoxins - Importance of detoxification pathways and binders Thank you to our episode sponsor: ⁠⁠⁠⁠⁠Liver Medic⁠⁠⁠⁠⁠⁠ Use code Chloe20 to save 20% on ⁠⁠⁠⁠⁠⁠⁠"Leaky Gut Repair"⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠Brendan's YouTube Channel⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠https://x.com/livermedic⁠⁠⁠⁠⁠⁠⁠ Thanks for tuning in! Get Chloe's Book Today! "⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠75 Gut-Healing Strategies & Biohacks⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠" Follow Chloe on Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@synthesisofwellness⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow Chloe on TikTok @chloe_c_porter Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠synthesisofwellness.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ to purchase products, subscribe to our mailing list, and more! --- Support this podcast: https://podcasters.spotify.com/pod/show/chloe-porter6/support

Dr. Zahra Kashi and Russell Martin share how Kashi Laboratory developed their HLA molecular testing menu and how they expanded into non-HLA molecular diagnostics. Tune in to find out what non-HLA molecular diagnostic testing may be the future for HLA laboratories.

Dr. Pedro Barata and Dr. Lillian Siu discuss recent advances in cancer vaccines and biomarkers, including the potential of the neoantigen and immune modulatory vaccines and the challenges surrounding cancer vaccine development. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host for the ASCO Daily News Podcast today. I'm a GU medical oncologist at the University Hospitals Seidman Cancer Center in Cleveland, Ohio, and an associate professor of medicine at Case Western Reserve University School of Medicine. I'm also an associate editor of the ASCO Educational Book. And today we'll be discussing a timely article that was recently published in the Educational Book titled, “State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers.”   I'm delighted to welcome one of the article's co-authors and a world-renowned oncologist, Dr. Lillian Siu. She is a senior medical oncologist and director of the Phase 1 Program at the Princess Margaret Cancer Center and a professor of medicine at the University of Toronto.  Welcome, Dr. Siu. Dr. Lillian Siu: Thank you, Dr. Barata; it's great to be here. Dr. Pedro Barata: Wonderful. Dr. Siu will discuss new tools for cancer vaccine development, strategies for combating the immunosuppressive and tumor microenvironment. She will also address cancer vaccine guidelines and patient recruitment strategies to optimize patient selection and access to cancer vaccine trials. I should say that Dr. Siu and her co-authors also addressed this topic during an Education Session at the ASCO 2024 Annual Meeting.  Finally, our full disclosures are available in the transcript of this episode.  So again, Dr. Siu, great to be speaking with you today. I'm looking forward to our discussion.  Dr. Lillian Siu: Thank you, Dr. Barata. And before I begin, I want to acknowledge Dr. Jeffrey Weber and Dr. Inge Marie Svane, who both presented during the ASCO session you mentioned. They gave excellent presentations related to the topic of neoantigen vaccines and immune-modulatory vaccines, which we will talk about later. Dr. Pedro Barata: Wonderful. So let's get started. Cancer vaccines are among the most promising frontiers for breakthrough innovations and new strategies in the fight against cancer. The successes in vaccine development during the COVID-19 pandemic, I think, inspired further research in this area. Why do you think it's important that we harness these recent successes and technological advances to really accelerate progress in vaccine development? Dr. Lillian Siu: Absolutely. I think all of us who have lived through COVID really appreciated how important the COVID vaccine development was to all of us. It saved millions of lives. And I think we witnessed a paradigm change in drug development that none of us thought was possible, that we're able to actually bring a concept to a drug from bench to bedside within an extremely short time. That timeline is not something we would ever imagine to have happened, and it did. And I think it gives us hope that perhaps this is not just limited to the COVID vaccine; it's also extrapolatable to other therapeutics – that we can bring promising medicines to our patients in a really expedited timeline, obviously without compromising their safety.  We now know that cancer vaccines have entered a new, or maybe I should say, renewed era of promise. And it's holding promise on many fronts, Pedro, if I may. It's very exciting in the area of molecular residual disease. In other words, a setting where the cancer is treated definitively by surgery or radiation, plus adjuvant treatment. And we know some patients will relapse because we know they're at high risk. And now we also have different ways to detect these microscopic risks, such as by ctDNA, circulating tumor DNA, or biomarkers. And we know that having some therapeutic that can eradicate these cancers at such microscopic levels would be very attractive, especially with low toxicity, and I think cancer vaccine is such a candidate. And of course, we can even look further into the future of using such treatment in cancer prevention, especially in those with high risk of developing cancer, for example, those with hereditary syndromes like lynch syndrome. We're not there yet, but I think it holds that promise.   So I think, going back to your original question, if we can develop such a therapeutic that is showing promise in a very short period of time, it brings the timeline and the hope to a much shorter timeframe to really deliver to our patients in a very timely manner while safeguarding all the important parts, such as safety and tolerability. Dr. Pedro Barata: Wow, those are such important points. I couldn't agree with you, more. It's really exciting. As I think through this, and as I was reading through your piece, I was thinking it would be great if you could highlight some of the novel approaches to personalized neoantigen vaccine development that are driving progress in this space. Dr. Lillian Siu: Absolutely. And during the session, Dr. Weber spoke about the neoantigen vaccine, and he's a pioneer in this space. So I can only try to iterate some of the points he had delivered during his talk. Neoantigen is a very exciting space for immunologists because we know that tumors express these neoantigens. Many of these are unique antigens that are only expressed in tumors, so-called tumor specific antigens, that we can use as our targets, including vaccines, but not limited to vaccines. And with these altered sequences in DNA in different forms, they could be mutations and splice alterations, etc. We expect that we have modified proteins that are expressed by tumor cells, and these become targets for our drug development of vaccines. And now we can have very specific strategies, very sophisticated algorithms to figure out which neoantigens are more so called immunogenic, more likely to stimulate or activate the immune system, and they can be recognized by T cells. So leveraging this knowledge and technology, we have been able to develop especially mRNA vaccines that are deliverable to our patients through different mechanisms, for example, in lipopeptides, etc., so that we can deliver to the patients in a safe way, such that we can use it to deliver vaccines, such as in the MRD setting that I mentioned earlier, as well as in the advanced disease setting. So Dr. Weber, in his presentation, highlighted one of such vaccines that have been tested in a randomized controlled trial that is KEYNOTE-942, which randomized 157 patients to the mRNA vaccine plus pembrolizumab versus pembrolizumab alone in patients with advanced melanoma. This is a vaccine against 34 mutated neoantigens, and it showed a significant difference in the recurrence free survival with a hazard ratio of 0.56. And if you look at the 18-month relapse free survival rate, it was 78.6% versus 62.2%. Obviously, these are still fairly early data and numbers are still small. I think we would definitely look forward to the randomized phase 3 study of neoantigen vaccine in melanoma and other cancers. Dr. Pedro Barata: No, absolutely. And I agree, it's really exciting. Dr. Weber did a fantastic job going through some of that data. So let me ask you Dr. Siu, as you think about this cancer vaccine field, what are the limitations that you'd highlight when you think about cancer vaccine development? What challenges do you encounter, obstacles do you encounter?  Dr. Lillian Siu: There are many, many potential challenges. And to some extent, that's probably why cancer vaccine development has been somewhat slow for the many decades until more recently. We know first of all; the target has to be recognized. So we need immunogenic targets. So I think a lot of the effort has been put into trying to understand which antigens expressed by cancer cells are immunogenic, able to activate the immune system. They're obviously assay based methods. You're going to try and see if you can ex vivo stimulate immune cells on dishes and models, etc. But we need to also develop in silico computerized algorithms, and now with AI, I think that makes it even more tangible and exciting that we can actually understand through a large number of neoantigens or other antigens, whether we can choose the ones that are most likely going to actually stimulate T cells to be activated. And I think that is one area that there is a lot of interest in development, how to really develop ways to select out the most attractive antigens.   I would also want to highlight that the platforms, which is how we deliver the vaccine, can also pose significant challenges. For example, vaccines can be delivered using peptide-based formulation, cell-based formulation, nucleic acids and viral vectors. For some of these formulations, for example, the peptides very often are restricted to HLA. They can be rapidly degraded in the body, such that they become not really visible to the T cells anymore. Some of the formulations can be very complex. For example, the cell-base; it may need to have cells isolated from patients, cultured, stored and transported to the site of delivery, which can be very complex. For some of the nucleic acid vaccines, they can have very low transfection efficiency. It could be at risk for also having, for example, DNA vaccines integrated into the host genome. And then lastly, there's also the immune suppressive environment in the TME, such that it does not really have the effect when you give it repeatedly. It becomes attenuated and no longer effective. So these are some of the challenges associated with cancer vaccines.  Dr. Pedro Barata: Thank you for that summary. I think it's really important for folks out there, including researchers getting into this field, to be aware of potential obstacles they might encounter.  So let me ask you the opposite question as we see more compelling preclinical and clinical data emerging in this field of vaccine development, what is really exciting you the most about the newest technologies that are shaping the future of cancer vaccines, in your opinion?  Dr. Lillian Siu: I think one I want to highlight is the immune-modulatory vaccine that Dr. Svane, Dr. Inge Marie Svane had presented during the presentation at ASCO. This is a completely different strategy from the neoantigen vaccine. It targets antigens in the tumor microenvironment. And we know that in the tumor microenvironment, we have tumor cells, we have immune cells, and there are many types of cell types, including, for example, macrophages, cancer associated fibroblasts, regulatory T cells, etc. And using these particular cell types, we know that we can really develop vaccines that can stimulate the body's immune system to attenuate, to downgrade some of the negative factors in the tumor microenvironment. And this is what Dr. Svane and her group is trying to do. For example, they have an IDO vaccine that is able to actually target these antigens in the tumor microenvironment, and by that, not just suppressing the negative forces, so to speak, but also activate T cells to help attack cancer cells. I think that's a very interesting area. Very early promise has been seen already in non-small cell lung cancer in early phase trials using the immune-modulatory vaccine.  But going back to your question, what kind of advances; I mentioned earlier about having novel ways to select our antigens that are most immunogenic. There are many algorithms that are being developed, and I think we can try and leverage that kind of knowledge from artificial intelligence, machine learning. So I think that's definitely very exciting. There are also new vaccine platforms coming out. For example, there's recent data using modification of peptides, so called amphiphile vaccines, that already show very early promise in colorectal cancer, microsatellite status, colorectal cancer, as well as in pancreatic cancer in the molecular residual disease setting, where these long peptide vaccines targeting KRAS mutants together with adjuvant oligonucleotide DNA, combined together, can actually be given to patients and reduce the chance of cancer relapse in patients with resected colorectal cancer, as well as pancreatic cancer, with endpoints such as ctDNA or biomarker being downregulated. I think that's a very exciting example. Another very exciting example is cell-based vaccines that are being developed in Europe by the NKI Netherlands Cancer Institute Group, where they are looking at plasmacytoid dendritic cells that are loaded with peptides from different tumor associated antigens and then given to patients, which, again, in non-small cell lung cancer, together with pembrolizumab, has yielded very high response rate. And we will almost certainly see more trials coming out using that particular platform with the dendritic cells. So that's just some of the examples of exciting things that are happening in the vaccine field. Dr. Pedro Barata: Thank you. I'm wondering if you can share with our listeners about what really are the existing guidelines for using these new tools for discovery, methods of treatment, and perhaps optimizing patient selection to access trials.  Dr. Lillian Siu: To be honest, the latest guideline that was published from the FDA that I can find is almost 13 years ago in 2011. So I think it is time for a new guidance, or at least a draft guidance, to give some additional support and guidance in terms of what to do with these new treatments from the FDA and perhaps other regulatory agencies as well. I think we're now entering a very exciting time that cancer vaccines are no longer an ineffective therapeutic. It is now showing evidence of efficacy, not just in the advanced setting, but also in the molecular residual disease setting. There're so many questions to be answered, like how to develop these trials in early disease; what's the end point? Can we incorporate them into the neoadjuvant setting, and if so, how do we give these drugs before surgery, and do we give them maintenance after surgery? I think guidance from the regulatory authorities would be extremely helpful and informative to guide academic groups as well as the pharmaceutical sector to develop these agents in the right way. Dr. Pedro Barata: Dr. Siu, this is a fantastic summary, and we certainly are on the cusp of a new dawn of discovery and development in cancer vaccines, and super interesting to hear from you talking about it. Before letting you go, do you have any final thoughts that you'd like to share with the listeners, with all of us about this topic? Dr. Lillian Siu: I think as a drug developer like you are, I'm extremely excited because we now have yet another way to leverage the host immunity as a cancer therapeutic, and it is going to be opening a new door to combination therapy because we can imagine combining these treatments with other immunotherapeutics such as bispecific molecules such as CAR Ts and even vaccine plus vaccine combination is feasible. That came up actually during the session as a question from the audience. Can we combine neoantigen vaccines and immune-modulatory vaccines together? And both of our speakers who presented felt that it was possible. Obviously, we have to understand the sequence question and the endpoints question, but the fact that it opens a new door to combinatorial therapy, not just with immunotherapeutics, but perhaps with other therapeutics as well, antibody drug conjugates, etc., really, I think, is very exciting for this field to become further explored.  I mentioned earlier in the podcast that the whole area of cancer prevention is something that we have not been tapping into for the last decade with vaccines because it has not been very effective. Viral vaccines, of course, HPV and other vaccines targeting viruses, but targeting cancer cells is not something we have been successful using vaccines to prevent cancer from developing. I think we would be very interested to see if this will become a reality in the next decade. I think we would start off with patients with high risk of developing cancers such as, as I mentioned earlier, those with lynch syndrome, those harboring BRCA alterations, for example. Can we use these vaccines to actually prevent the cancers from developing in such high-risk individuals? I think the field is definitely open to that consideration.  Dr. Pedro Barata: Definitely. And I'd like to thank you, Dr. Siu, for sharing these great insights with us today on the ASCO Daily News Podcast. Dr. Lillian Siu: Thank you so much for your time.  Dr. Pedro Barata: And thank you to all the listeners for your time today. You'll find a link to the article discussed today in the transcript of this episode, and I encourage you to check out the 2024 ASCO Educational Book. Finally, if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. So again, thank you so much for your time and see you soon.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:  Dr. Pedro Barata  @PBarataMD  Dr. Lillian Siu  @lillian_siu   Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures:    Dr. Pedro Barata: Honoraria: UroToday  Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Dendreon  Speakers' Bureau (Inst): Caris Life Sciences, Bayer, Pfizer/Astellas  Research Funding (Inst.): Blueearth, AVEO, Pfizer, Merck    Dr. Lillian Siu:  Leadership (Immediate family member): Treadwell Therapeutics  Stock and Other Ownership Interests (Immediate family member): Agios   Consulting or Advisory Role: Merck, AstraZeneca/MedImmune, Roche, Voronoi Inc., Oncorus, GSK, Seattle Genetics, Arvinas, Navire, Janpix, Relay Therapeutics, Daiichi Sankyo/UCB Japan, Janssen, Research Funding (Institution): Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, AstraZeneca, Boehringer Ingelheim, Bayer, Amgen, Astellas Pharma, Shattuck Labs, Symphogen, Avid, Mirati Therapeutics, Karyopharm Therapeutics, Amgen

Chuck Staton and Brad Roeher of Funbearable chat it up with Codex Prime in this week's episode about everything from weird/bad dates, HLA, and more! Victor also showcases his latest haul from the Barnes & Noble July Criterion Collection sale, Carl highlights the new Sandra Bullock Netflix film Unforgivable and the new Beverly Hills Cop sequel Axel F., and Victor also highlights the new films Monkey Man and Late Night with the Devil. We believe in Joe Hendry, so let's GET IT! Recorded July 9, 2024 ---------------------------------------------------------------------------------- Catch Codex Prime on Spotify, Apple Podcasts, or other podcast platforms. Email: CodexPrimePodcast@gmail.com SOCIAL MEDIA: Facebook: www.facebook.com/codexprime Twitter: twitter.com/codexprimecast Instagram: instagram.com/codexprimepodcast/ YouTube: www.youtube.com/channel/UCbDMNJNgnM6y3WB3fA1a1HA SoundCloud: @codex-prime Victor Omoayo - Do the Film Thing Podcast: https://dothefilmthing.podbean.com/ - Do the Film Thing Linktree: https://linktr.ee/dothefilmthing - Email: dothefilmthing@gmail.com Carl Byrd - Twitter, Instagram, TikTok and Mixcloud @mrbyrd1027

CIRS Coach Ruth DiTulio of Regenix Healing guest hosts! She discusses: the HLA gene and a thorough definition of CIRS (Chronic Inflammatory Response Syndrome). What are Ruth's Top 5 Root Causes of IBD that she observes with her clients, and what is crucial blood testing for biotoxin illness—for wider and limited budgets? ✅ This is a MUST LISTEN for anyone who wants to find their IBD root cause! Consult with Ruth at: https://cirscoach.com